Browse the evidence

Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Practitioners should adopt a long-term management strategy for obesity treatment.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

NN501 causes weight loss without causing obvious aversive responses.

NN501 may provide a weight loss option without the side effects commonly associated with other treatments.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of corticosteroid use in patients with inflammatory bowel disease (IBD) compared to non-GLP-1 users.

Clinicians can consider GLP-1RAs for weight management in IBD patients without concern for increased corticosteroid use.

Up to 33% of the weight lost on GLP-1 RAs may be lean tissue mass.

Practitioners should monitor body composition changes in patients using GLP-1 RAs.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

GLP-1RAs may raise safety concerns related to weight loss and altered glucose regulation in ALS.

Monitoring for weight loss and glucose regulation is essential when considering GLP-1RAs for ALS.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689) and 24 months postoperatively (5% vs. 7%; OR=0.692).

GLP-1RAs may help reduce the need for reoperation in ACDF patients.

GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF.

GLP-1RAs may significantly improve postoperative outcomes in ACDF patients.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.

Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.

GLP-1RAs provide direct neurovascular protection by stabilizing the blood-brain barrier and modulating neuroinflammation.

GLP-1RAs may be beneficial in protecting brain health and reducing stroke risk.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Excess visceral abdominal fat (EVAF) can occur in people living with HIV-1 even with normal or mildly elevated body mass index (BMI).

Healthcare providers should assess visceral fat in PLWH regardless of BMI.

There were no significant differences in the amount of weight lost between semaglutide 0.5 mg and liraglutide 3 mg after 3 months.

Clinicians can expect similar weight loss outcomes from either treatment option.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.

GLP-1RAs are being studied in clinical settings not previously examined in original trials.

Practitioners should stay informed about the evolving applications of GLP-1RAs in clinical practice.

Patients who have undergone significant weight loss are at increased risk of thromboembolic events, particularly after body contouring procedures.

Practitioners should monitor thromboembolic risk in post-weight-loss patients undergoing surgery.

There have been some adjustments in weight reduction medications available on the German market in the last two years.

Stay updated on the latest weight reduction medications available in Germany.

The article provides an outlook on new weight reduction medications that are about to be approved or are currently in Phase 3 of approval studies.

Be aware of new medications that may soon be available for weight reduction.

Several factors contribute to obesity-related vasodilator dysfunction, including vascular insulin resistance and lipotoxicity.

Understanding these factors can guide targeted interventions for managing vascular health in obese patients.